Chronic Rhinosinusitis with Nasal Polyposis: Emerging Data and New Insights for Treatment

Activity Overview

Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with significant morbidity and negative impact on patient quality of life. Recent developments have uncovered numerous potential treatment approaches for CRSwNP by targeting type 2 inflammatory pathways; however, only patients expressing these immune phenomena will respond to these novel treatment approaches. This interactive infographic will cover the diagnosis, pathophysiology, and new/emerging treatment strategies for CRSwNP, including demonstrative case challenges, questions, audio narration, and interactive educational diagrams.

0.50 CE Credit(s)

Target Audience

The target audience for this activity is allergy-immunology, ENT, and pulmonology clinicians (MD/DO/NP/PA) managing patients with CRSwNP.

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Accurately diagnose patients with Th2-driven nasal polyps (chronic rhinosinusitis with nasal polyps [CRSwNP]) who may be eligible for treatment with biologic therapy
  • Describe the underlying pathophysiology of rhinosinusitis-associated nasal polyps and how this may be used to guide selection of novel biologic therapy
  • Evaluate emerging agents for CRSwNP based on their efficacy and safety data

Activity Faculty

Bradley E. Chipps, MD, FAAP, FACAAI, FAAAAI, FCCP

Bradley E. Chipps, MD

Medical Director, Respiratory Therapy
Sutter Medical Center
Capital Allergy and Respiratory Disease Center
Sacramento, CA